| Literature DB >> 34203179 |
Cong-Peng Zhao1, Guo-Ying Chen1, Yuan Wang1, Hua Chen1, Jia-Wen Yu2, Feng-Qing Yang1.
Abstract
In this study, a polydopamine (PDA)-modified hollow fiber-immobilized xanthine oxidase (XOD) was prepared for screening potential XOD inhibitors from flavonoids. Several parameters for the preparation of PDA-modified hollow fiber-immobilized XOD, including the dopamine concentration, modification time, XOD concentration and immobilization time, were optimized. The results show that the optimal conditions for immobilized XOD activity were a dopamine concentration of 2.0 mg/mL in 10.0 mM Tris-HCl buffer (pH 8.5), a modification time of 3.0 h, an XOD concentration of 1000 μg/mL in 10.0 mM phosphate buffer (pH 7.5) and an immobilization time of 3.0 h. Subsequently, the enzymatic reaction conditions such as the pH value and temperature were investigated, and the enzyme kinetics and inhibition parameters were determined. The results indicate that the optimal pH value (7.5) and temperature (37 °C) of the PDA-modified hollow fiber-immobilized XOD were consistent with the free enzyme. Moreover, the PDA-modified hollow fiber-immobilized XOD could still maintain above 50% of its initial immobilized enzyme activity after seven consecutive cycles. The Michaelis-Menten constant (Km) and the half-maximal inhibitory concentration (IC50) of allopurinol on the immobilized XOD were determined as 0.25 mM and 23.2 μM, respectively. Furthermore, the PDA-modified hollow fiber-immobilized XOD was successfully applied to evaluate the inhibitory activity of eight flavonoids. Quercetin, apigenin, puerarin and epigallocatechin showed a good inhibition effect, and their percentages of inhibition were (79.86 ± 3.50)%, (80.98 ± 0.64)%, (61.15 ± 6.26)% and (54.92 ± 0.41)%, respectively. Finally, molecular docking analysis further verified that these four active compounds could bind to the amino acid residues in the XOD active site. In summary, the PDA-modified hollow fiber-immobilized XOD is an efficient method for the primary screening of XOD inhibitors from natural products.Entities:
Keywords: PDA-modified hollow fiber; enzyme immobilization; flavonoids; inhibitory activity; xanthine oxidase
Mesh:
Substances:
Year: 2021 PMID: 34203179 PMCID: PMC8271864 DOI: 10.3390/molecules26133931
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1FT-IR spectra of hollow fiber and hollow fiber modified by PDA (A); (a) is hollow fiber and (b) is hollow fiber modified by PDA. SEM images of hollow fiber and hollow fiber modified by PDA (B); (a) and (b) are hollow fiber at 3.0 kV × 2000 and 3.0 kV × 5000, and (c) and (d) are hollow fiber modified by PDA at 3.0 kV × 2000 and 3.0 kV × 5000.
Figure 2Effects of concentration of DA (A) and stirring time (B) on the activity of PDA@HF-immobilized XOD (the optimal activities of the immobilized enzyme counterpart were taken as 100%).
Figure 3Effects of XOD immobilization time (A) and XOD amount (B) on the activity of PDA@HF-immobilized XOD (the optimal activities of the immobilized enzyme counterpart were taken as 100%).
Figure 4Effects of pH (A) and temperature (B) on the activity of free XOD and immobilized XOD (the optimal activities of the immobilized enzyme and free enzyme counterparts were taken as 100%).
Figure 5Double reciprocal plot at varied concentrations of substrate ranging from 0.07 to 0.7 µM (A). The inhibition curve for allopurinol on PDA@HF-immobilized XOD (B).
Figure 6The reusability of XOD@PDA@HF.
The percentage of inhibition of eight flavonoid compounds on XOD@PDA@HF.
| Compounds | % of Inhibition | Compounds | % of Inhibition |
|---|---|---|---|
| Quercetin | 79.86 ± 3.50 | Epicatechin | 16.61 ± 3.03 |
| Apigenin | 80.98 ± 0.64 | Epigallocatechin | 54.92 ± 0.41 |
| Puerarin | 61.15 ± 6.26 | Epicatechin gallate | 26.80 ± 5.78 |
| Catechin | 28.68 ± 0.60 | Epigallocatechin gallate | 33.07 ± 3.39 |
Docking results of four flavonoids and allopurinol with XOD.
| Compounds | Binding Energy (Kcal/mol) | Amino Acid Residues | Hydrogen Bonds |
|---|---|---|---|
| Allopurinol | −5.68 | GLY796, MET1038, GLY797, GLN1040, CYS150, PHE798, ARG912, GLN1194 | GLY797, GLN1194, CYS150, MET1038 |
| Quercetin | −5.81 | ALA338, GLY339, GLY46, GLY47, ARG426, SER1225, LYS1228, ALA1231, ILE1229, LEU147 | GLY46, GLY47, ARG426, LYS1228, ILE1229 |
| Apigenin | −6.74 | GLU45, GLY47, LEU147, ALA338, TYR1227, LYS1228 | GLU45, TYR1227 |
| Puerarin | −6.54 | GLN144, TRP336, GLY1233, SER1234, ARG426, ALA424, LYS1228 | GLN144, SER1234, GLY1233 |
| Epigallocatechin | −6.98 | GLN144, TRP336, ALA1231, LEU147, GLY47, ILE1229, LYS1228, TYR1227 | TYR1227, GLY47, GLN144, ILE1229, TRP336 |
Figure 7Molecular docking of quercetin (a), apigenin (b), puerarin (c), epigallocatechin (d) and allopurinol (e) with XOD.
Figure 8Schematic diagram of PDA-modified hollow fiber-immobilized XOD.